Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer's Intervention by 4.5 Years, AAIC 2025 Presentation Findings Show
Progress in validating in-home blood test, combined with cognitive assessment and specialty virtual care, break through barriers to early detection
Key Takeaways
Findings from breakthrough approach to early detection for Alzheimer's disease (AD) has the potential to reduce time from earliest development of symptoms to care by 4.5 years are presented at the AAIC 2025.
Results show strong correlation between TASSO vs. traditional phlebotomist blood draw/capillary collection with the potential to successfully triage patients.
New ecosystem brings together in-home biomarker testing and a cognitive assessment with virtual care to reduce multiple barriers to the early detection and treatment of Alzheimer's disease.
Neurogen's online platform offering in-home blood testing for Alzheimer's disease for people with memory concerns is in beta test and readies for national launch – offers a potential solution to meet the urgent global demand for faster adoption and equitable access to breakthrough testing technologies for early detection of AD.
CHICAGO, July 28, 2025 (GLOBE NEWSWIRE) -- Advancements in accelerating early Alzheimer's disease screening and access to care proven from three diverse community pilot initiatives were presented today during a podium presentation at the Alzheimer's Association International Conference® 2025 (AAIC). The study entitled, 'Remote Collection of Biomarkers for Alzheimer's Disease and Related Disorders' was designed to validate Neurogen's new ecosystem that brings together the first in-home biomarker testing and a cognitive assessment with virtual care. Study findings suggest that the ecosystem has the potential to reduce the time from earliest development of symptoms to care by 4.5 years breaking down multiple barriers to early detection and treatment of Alzheimer's disease. The study also validated a strong correlation between TASSO vs. traditional phlebotomist blood draw/capillary collection suggesting TASSO's potential to successfully triage patients.
'We created a new model to reach those with Mild Cognitive Impairment (MCI),' said Elisabeth Thijssen, PhD, Chief Scientific Officer, Neurogen Biomarking and the session presenter whose research focus for nearly a decade has been on blood-based biomarkers for AD and specifically P-tau217. 'Neurogen's ecosystem is built to meet the urgent global demand for faster adoption of breakthrough testing technologies for early detection of AD. Our mission is to give everyone equal access to cutting-edge technology to detect Alzheimer's early—when treatment can make the greatest impact on the course of people's lives.'
The findings come from three free community events targeting people aged 50 years and older held at local hospitals in Chicago, Illinois; Flint, Michigan; and Coldwater, Michigan to sign up participants. Participants were recruited through community engagement, traditional and social media and mobilization of communications targeting area health and wellness organizations.
About the Screenings
Event participants began the screening with an advanced digital cognitive assessment and a brief lifestyle survey.
Every participant did the traditional IV venous blood draw performed by a licensed professional. The TASSO, non-invasive method that allows for blood collection without the need for a needle was offered and optional.
All samples were preserved through ambient shipment, maintaining integrity without the need for refrigeration or freezing.
IV samples were analyzed using the ALZpath P-tau217 assay, a validated ultrasensitive biomarker test that closely correlates with Alzheimer's pathology.
Testing was conducted in CLIA- and CAP-certified laboratories, ensuring clinical accuracy and regulatory compliance with results within days and a follow up via telehealth counseling with a board-certified neurologist if needed.
Study Results
A total of 455 participants received biomarker and digital cognitive testing:
66% were Women
Average age was 67
45% were White/Caucasian
39% were Black/African American
16% did not report
Among the 455 test participants, 26 percent had elevated P-tau217 concentrations
Eighty percent had some form of cognitive impairment as is typical in this kind of event
TASSO could identify elevated P-tau217 with 88% accuracy and meets the performance requirement for AD triaging in a broader population.
Participants with elevated test results received follow up care via telehealth from board certified neurologists within days.
The Neurogen ecosystem reduced the time from cognitive concerns to intervention by 4.5 years—changing the standard time from the emergence of cognitive concerns from years (3 to 6 years) to months (4 months to 1.5 years).
'In one-day events held in three different U.S. communities reaching people with no prior dementia diagnosis, we found 18 percent tested positive for P-tau217 and an additional eight percent were intermediate,' Dr. Thijssen stated. 'Bringing these people immediately into virtual care with a neurologist who shared the test results and provided a personalized brain health action care plan was heartening given the long wait time to see a specialist once a patient expresses memory concerns to their primary care physicians that is now typical in the US.'
Neurogen's online ecosystem offers in-home testing for Alzheimer's disease for people with memory concerns and virtual follow up care with board-certified neurologists. It is now in beta test and readies for national launch.
The Unmet Need: Access to Early Detection Testing for Alzheimer's
An estimated 40% of Americans aged 65 and older—representing more than 16 million people—experience some form of memory impairment¹. Yet, fewer than 8% of older adults living with Mild Cognitive Impairment (MCI) ever receive a formal diagnosis, leaving 92% without answers or access to early intervention². On average, there is a staggering 6- to 8-year delay from the onset of symptoms to diagnosis—even though today's treatments are most effective when administered in the earliest stages of disease3. Further compounding the issue, fewer than one in five Alzheimer's diagnoses in the U.S. currently involve biomarker testing, due in large part to gaps in accessibility and clinical expertise³. These data underscore an urgent call to transform how Alzheimer's and cognitive decline are detected and managed—especially as the aging population grows and new diagnostic tools become available.
About Neurogen
Neurogen Biomarking is on a global mission to give everyone equitable access to brain health care. The company offers the first at-home blood biomarker test for phosphorylated (P-tau217) using proprietary blood collection technology and advanced digital cognitive testing with results guided by board-certified neurologists via telehealth. Neurogen's vision is to deliver accessible technology, actionable insights, and pathways to precision-based proactive care to support early detection and care for Mild Cognitive Impairment (MCI) and dementia associated with Alzheimer's disease (AD). Neurogen was founded by award-winning neurologist Dr. Rany Aburashed and developed with co-founders Elisabeth Thijssen, PhD, Chief Scientific Officer, and Ken Bahk, Chief Strategy Officer. The company is guided by a team of world-renowned brain health experts www.neurogenbiomarking.com.
Media Contacts:Reilly Connect for Neurogen BiomarkingAshley.Biladeau@reillyconnect.com952.994.4021 -or-Mia.joan@reillyconnect.com872.240 3696
Citations
Small, G.W. (2002). What we need to know about age-related memory loss. BMJ, 324(7352), 1502–1505. https://doi.org/10.1136/bmj.324.7352.1502
Liu, J. L., Hlavka, J. P., Coulter, D., Baxi, S. M., & Mattke, S. (2023).Barriers to the Use of Alzheimer's Disease Biomarkers in Clinical Practice. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 15(1), e12417.https://doi.org/10.1002/dad2.12417
Alzheimer's Association. (2023). 2023 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia, 19(3), 159–258. https://doi.org/10.1002/alz.13016
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf44512c-4bea-4251-a912-6638686682c9Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 minutes ago
- Associated Press
Federal officials to take over inspections when troubled Boar's Head plant reopens
Federal inspectors will assume direct oversight of a troubled Boar's Head deli meat plant when it reopens after last year's deadly listeria outbreak, U.S. Agriculture Department officials said. The Jarratt, Virginia, factory is set to resume operations in the coming months. It will face at least 90 days of heightened monitoring and inspections by federal Food Safety and Inspection Service officials. Previously, inspections were conducted by state officials who operated on behalf of the agency. The change aims to 'ensure the establishment consistently and effectively implements its corrected food safety plans,' USDA officials said in a statement. It calls for stricter enforcement if lapses occur. The plant was shuttered nearly a year ago when listeria-tainted liverwurst caused the outbreak that killed 10 people, sickened dozens and forced a recall of more than 7 million pounds of deli products. USDA officials lifted the plant's suspension in July. In the years before the outbreak, state inspectors documented numerous problems at the plant, including mold, insects, liquid dripping from ceilings and meat and fat residue on walls, floors and equipment, records showed. They were operating under a cooperative agreement, the Talmadge-Aiken program, that allows state inspectors to conduct federal inspections. The shift to direct federal oversight underscores the severity of the problems at the Boar's Head plant, said Sandra Eskin, a former USDA official who now heads STOP Foodborne Illness, a consumer advocacy group. It raises concerns about communication between state and federal officials when problems occur, she added. 'Given its history, it's particularly important that there be robust oversight of that plant,' Eskin said. Boar's Head officials said in a statement that they have worked with state and federal regulators 'to ensure the successful and safe reopening of the Jarratt facility.' The company said it has boosted food safety practices in Jarratt and other sites aimed at reducing or eliminating listeria in finished products. The company has declined to comment on documents obtained by The Associated Press that showed that sanitation problems persist at other Boar's Head sites in three states. Between January and July, inspectors in Arkansas, Indiana and a second site in Virginia reported problems that include instances of meat and fat residue left on equipment and walls, drains blocked with meat products, beaded condensation on ceilings and floors, overflowing trash cans and staff who didn't wear protective hairnets and plastic aprons or wash their hands. Officials at the 120-year-old company based in Sarasota, Florida, hired a chief food safety officer in May. It also brought in a panel of experts, including Mindy Brashears, a food safety expert nominated by President Donald Trump for a second term as the USDA's undersecretary for food safety. Brashears, who now directs a food safety center at Texas Tech University, did not respond to requests for comment about Boar's Head. An automatic email reply said she was traveling out of the country until next week. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
29 minutes ago
- Yahoo
Acorn Health Names Mony Iyer CEO
CORAL GABLES, Fla., August 21, 2025--(BUSINESS WIRE)--Acorn Health, a leading national provider of applied behavior analysis (ABA) therapy for children diagnosed with autism spectrum disorder (ASD), announces Mony Iyer as its new president and chief executive officer, effective Sept. 15, 2025. "We are delighted to welcome Mony to Acorn Health," said Imran Siddiqui, a member of Acorn Health's board of directors and managing director of Ontario Teachers' Pension Plan. "A nationally recognized business leader, he brings the unique combination of championing culture and inspiring teams while scaling organizations with purpose. We are excited to support him as he leads Acorn Health into its next stage of growth and impact." Iyer has more than 20 years of experience leading large, mission-driven organizations. Most recently, he served as president of Banfield Pet Hospital, one of the largest veterinary companies in the US. Prior to that he was vice president of specialty healthcare services for Walmart, president of OneSight and vice president for Luxottica Group. "What drew me to Acorn Health is its clear mission and strong culture of care," said Iyer. "Over the course of my career, I have experienced how empowering teams and clinicians leads to better outcomes for those we serve. I am eager to build on that foundation by investing in and strengthening our teams that provide such critical care to our clients, expanding access for families, and ensuring that Acorn continues to grow in a way that reflects its values." Iyer holds a bachelor's degree in electronics and communication engineering from The University of Madras, a master's degree in electrical engineering, and an MBA from Duke University. Rich Hallworth, who has led Acorn Health since 2023, will retire from the CEO role and continue to serve as an active member of Acorn Health's board of directors. "It has been a privilege to lead Acorn Health and to work alongside such a talented team," Hallworth said. "As I transition into retirement, I am pleased to remain an active member of the board and continue supporting the organization's mission. I have full confidence in Mony's leadership and in the team's ability to carry Acorn forward." About Acorn Health: Acorn Health is accredited by the Autism Commission on Quality and offers both center-based and in-home services nationwide in more than 70 centers located throughout Florida, Illinois, Maryland, Michigan, Pennsylvania, Tennessee, and Virginia. Founded in 2018, Acorn is committed to providing industry-leading quality clinical care through applied behavioral analysis (ABA) therapy to give children diagnosed with autism spectrum disorder (ASD) the opportunity to live more independent and meaningful lives. Cases of ASD are on the rise; according to the Centers for Disease Control and Prevention, one in 31 children is living with ASD. ABA therapy, a program endorsed by the U.S. Surgeon General, provides individualized plans for each patient based on agreed upon clear, measurable goals with the child's family. Acorn Health uses its proprietary Behavioral Health Index to measure success in ways that are easily understood by families, clinicians and educators. To learn more about Acorn Health, visit and to learn about career opportunities, visit To inquire about ABA therapy at Acorn Health, please call 844.244.1818. Follow us at and View source version on Contacts Media contact: Lynne Blasi, 703.582.3973, lynne@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
30 minutes ago
- Gizmodo
Man Experiences Joy For the First Time in Decades After Brain Stimulation Treatment
A man who lived with severe, treatment-resistant depression for over 30 years is now in remission, thanks to a new brain stimulation method that targets selective areas of his brain. The man reported experiencing joy for the first time in decades after the treatment. 'He was crying and saying, 'I'm not sad, I'm just happy. I don't know what to do with these emotions',' the study's first author, Ziad Nahas, a psychiatrist and professor at the University of Minnesota, told Gizmodo. Nahas and a team of researchers across several universities developed a personalized method to implant electrodes and precisely send weak electrical signals into brain areas believed to be involved in depression. By fine-tuning this stimulation using the patient's feedback, the treatment has relieved the participant's symptoms for up to two years. Their findings are detailed in a new preprint on PsyArXiv, which has not yet been peer-reviewed. The study's single participant initially contacted the researchers while they were recruiting for a new clinical trial. At the time, he had been living with treatment-resistant depression for three decades, having first been hospitalized at age 13. Since then, he had undergone multiple hospitalizations and tried dozens of treatments alongside intensive psychotherapy. He had also attempted suicide three times. Treatment-resistant depression is a common form of major depressive disorder that does not improve significantly after at least two standard treatment attempts, such as medications or therapy. In such cases, electroconvulsive therapy (ECT)—which stimulates the brain using weak electrical currents—is often considered a next step. While ECT has been used for decades and can be effective for some patients, it fails for others. In this patient's case, brain stimulation had previously failed to alleviate any symptoms. He had undergone two courses of electroconvulsive stimulation therapy. The first was moderately effective, but the second and third brought no relief. The problem is that most ECT studies stimulate specific brain areas based on a standard brain atlas, Damien Fair, a neuroscientist and professor at the University of Minnesota and a study co-author, explained to Gizmodo. That means that researchers don't often know exactly which area they're targeting, since everyone's brain is different. 'It's a one-size-fits-all approach,' said Fair. To address this, the team developed a personalized stimulation method tailored to the participant's brain. First, they used functional MRI (fMRI) to map the borders of his brain networks previously linked to depression. This revealed that the patient's salience network, which processes external stimuli, was about four times larger than in people without depression, potentially contributing to his symptoms, Fair said. Next, the researchers surgically implanted four clusters of electrodes into the brain, over the borders of these brain networks. A few days later, they began sending electrical signals into each of the four networks individually. When they stimulated the default mode network (DMN), a group of regions linked to internal thought processes, the patient began to experience happiness. Nahas immediately called Fair. '[Nahas] said, 'You won't believe it. We stimulated the default network, and [the participant] is breaking down in tears of joy,'' Fair recalled. Stimulating the action-mode network, which is involved in planning, and the salience network both led the man to report a sense of calm. Targeting the frontoparietal network, which is involved in decision-making, resulted in improved focus. Over the next six months, the patient received electrical stimulation in the various brain networks each day for 1 minute, every 5 minutes. The researchers continued to adjust the stimulation settings each month using a statistical method that incorporated the patient's daily feedback. By seven weeks post-surgery, the participant no longer experienced suicidal thoughts. By six months, his symptoms had significantly improved. By nine months, he had entered full remission. That remission has lasted for two years. 'The uniqueness of PACE is combining very precise, individualized targeting of multiple networks and tuning the parameters so the patient can receive the most benefit,' Nahas said. The team has since implanted a second participant and plans to implant a third. Ultimately, they aim to conduct a double-blind clinical trial. Nahas recently received an email from the original participant, who had embarked on a road trip with his family. He was enjoying his trip, he said. 'In psychiatry, we don't have cures,' Nahas said, 'but this is probably the closest we can get.'
